Quality Improvement in Stroke Prevention (QUISP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00328640|
Recruitment Status : Completed
First Posted : May 22, 2006
Last Update Posted : April 27, 2007
Is a secondary prevention intervention, focused on implementation of standardized pre-printed discharge orders for hospitalists, effective at increasing utilization of the following evidence-based treatments 6 months after discharge for ischemic stroke:
- Treatment with statins,
- Control of hypertension, and
- Anticoagulation in patients with atrial fibrillation.
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke||Drug: Optimal treatment||Phase 4|
There are several proven strategies for prevention of recurrent ischemic stroke, including use of statins, treatment of hypertension, and anticoagulation in patients with atrial fibrillation. Preliminary analyses suggest that only 9-15% of Kaiser Permanente Northern California’s ischemic stroke patients receive optimal care for secondary prevention of stroke. The purpose of this study is to determine whether or not a quality improvement (QI) intervention can improve the care received by stroke patients. This project consists of a randomized trial of standardized stroke discharge order forms to improve adherence with best practices in secondary stroke prevention. The primary research question is: Is a secondary prevention intervention, focused on implementation of standardized pre-printed discharge orders for hospitalists, effective at increasing utilization of the following evidence-based treatments 6 months after discharge for ischemic stroke: (1) treatment with statins, (2) control of hypertension, and (3) anticoagulation in patients with atrial fibrillation.
The primary outcome will be the proportion of patients receiving optimal treatment, as defined by these three goals. The impact of the intervention will be measures as a change after-to-before at intervention hospitals compared to non-intervention (control) hospitals, with the institution as the unit of analysis. Secondary analyses will evaluate the impact of the intervention on each of these components and on 6-month and 1-year rates of mortality, readmission for stroke, and costs of care after discharge.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1500 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Secondary Prevention After Ischemic Stroke: A Trial of an Evidence-Based System-Wide Intervention|
|Study Start Date :||December 2005|
|Actual Study Completion Date :||March 2007|
- Medication utilization
- Best Practices
- Recurrent stroke
- Hospital readmission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00328640
|United States, California|
|Kaiser-Permanente Division of Research|
|Oakland, California, United States, 94612|
|Study Director:||David M Grosvenor, MPH||University of California, San Francisco|
|Principal Investigator:||S C Johnston, MD||University of California, San Francisco|